Skip to content

ICG-based optoacoustic carotid plaque imaging using a contrast agent

Optoacoustic imaging of indocyanine green for identification of vulnerable atherosclerotic carotid plaques, a feasibility study - ICG-based optoacoustic carotid plaque imaging

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57839
Enrollment
10
Registered
2025-02-04
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carotid atherosclerotic plaques

Interventions

Patients will receive an intravenous injection of 0.5mg/kg ICG, and imaged with MSOT in the two hours prior to CEA.&nbsp
This MSOT imaging procedure will take approximately 15 minutes ande is comparable to a clinical ultrasound investigation of the carotid artery in supine position. Surgery is performed according to sta
will be transported to the pathology department to make ex vivo fluorescence images to visualize ICG. It will subsequently be snap frozen and transported to Erasmus MC for scanning in the MSOT (iThera

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients undergoing carotis endarterectomy. Patients must be > 18 years old and be able to give informed consent.

Exclusion criteria

Exclusion criteria: Major surgery within 28 days before tracer administration.Pregnant or nursing women, fertile women will need a negative pregnancy test prior to inclusion.History of iodine allergy or anaphylactic reactions to insect bites.Hypersensitivity to ICG or poorly tolerated ICG in the past.Unexplained allergic reaction in the past.Skin type > IV following Fitzpatrick skin classification (MSOT less reliable).

Design outcomes

Primary

MeasureTime frame
The main outcome is the technical feasibility of non-invasive optoacoustic imaging of ICG in carotid artery plaque. The findings are compared with ex vivo MSOT and fluorescence imaging results and histopathological analysis of the excised specimen.

Secondary

MeasureTime frame
see above

Countries

Netherlands

Contacts

Public ContactJ. Vonk

Universitair Medisch Centrum Groningen

j.vonk@umcg.nl0625649017

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 1, 2026